These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 26900287)

  • 1. Inflammation in irritable bowel syndrome: Myth or new treatment target?
    Sinagra E; Pompei G; Tomasello G; Cappello F; Morreale GC; Amvrosiadis G; Rossi F; Lo Monte AI; Rizzo AG; Raimondo D
    World J Gastroenterol; 2016 Feb; 22(7):2242-55. PubMed ID: 26900287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation and microflora.
    Pimentel M; Chang C
    Gastroenterol Clin North Am; 2011 Mar; 40(1):69-85. PubMed ID: 21333901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.
    Sinagra E; Morreale GC; Mohammadian G; Fusco G; Guarnotta V; Tomasello G; Cappello F; Rossi F; Amvrosiadis G; Raimondo D
    World J Gastroenterol; 2017 Sep; 23(36):6593-6627. PubMed ID: 29085207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The pathophysiology of irritable bowel syndrome: inflammation and motor disorder].
    Park H
    Korean J Gastroenterol; 2006 Feb; 47(2):101-10. PubMed ID: 16498275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irritable bowel syndrome: is the colonic mucosa to blame?
    Hoffman JM
    Neurogastroenterol Motil; 2012 Dec; 24(12):1051-3. PubMed ID: 23176660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulation of enteric neural function in irritable bowel syndrome.
    O'Malley D
    World J Gastroenterol; 2015 Jun; 21(24):7362-6. PubMed ID: 26139983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.
    Barbara G; Zecchi L; Barbaro R; Cremon C; Bellacosa L; Marcellini M; De Giorgio R; Corinaldesi R; Stanghellini V
    J Clin Gastroenterol; 2012 Oct; 46 Suppl():S52-5. PubMed ID: 22955358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship?
    Braak B; Klooker TK; Wouters MM; Welting O; van der Loos CM; Stanisor OI; van Diest S; van den Wijngaard RM; Boeckxstaens GE
    Am J Gastroenterol; 2012 May; 107(5):715-26. PubMed ID: 22488080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational agents for the irritable bowel syndrome.
    Ghaith O; El-Halabi M; Hashash JG; Sharara AI
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1161-78. PubMed ID: 20836617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome.
    Barbara G; Stanghellini V; Cremon C; De Giorgio R; Fronzoni L; Serra M; Corinaldesi R
    Dig Dis; 2009; 27 Suppl 1():115-21. PubMed ID: 20203507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets.
    Dupont HL
    Aliment Pharmacol Ther; 2014 May; 39(10):1033-42. PubMed ID: 24665829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome.
    Barbara G; Wang B; Stanghellini V; de Giorgio R; Cremon C; Di Nardo G; Trevisani M; Campi B; Geppetti P; Tonini M; Bunnett NW; Grundy D; Corinaldesi R
    Gastroenterology; 2007 Jan; 132(1):26-37. PubMed ID: 17241857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irritable bowel syndrome: emerging paradigm in pathophysiology.
    Lee YJ; Park KS
    World J Gastroenterol; 2014 Mar; 20(10):2456-69. PubMed ID: 24627583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irritable bowel syndrome: a clinical review.
    Chey WD; Kurlander J; Eswaran S
    JAMA; 2015 Mar; 313(9):949-58. PubMed ID: 25734736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal barrier defects in irritable bowel syndrome. Who left the door open?
    Barbara G
    Am J Gastroenterol; 2006 Jun; 101(6):1295-8. PubMed ID: 16771952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome.
    Matricon J; Meleine M; Gelot A; Piche T; Dapoigny M; Muller E; Ardid D
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1009-31. PubMed ID: 23066886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy of irritable bowel syndrome with anti-inflammatory cytokines.
    Kumar S; Singh P; Kumar A
    Clin J Gastroenterol; 2022 Feb; 15(1):1-10. PubMed ID: 34862947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is irritable bowel syndrome an inflammatory disorder?
    De Giorgio R; Barbara G
    Curr Gastroenterol Rep; 2008 Aug; 10(4):385-90. PubMed ID: 18627650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome.
    Camilleri M; Lasch K; Zhou W
    Am J Physiol Gastrointest Liver Physiol; 2012 Oct; 303(7):G775-85. PubMed ID: 22837345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations.
    Vicario M; González-Castro AM; Martínez C; Lobo B; Pigrau M; Guilarte M; de Torres I; Mosquera JL; Fortea M; Sevillano-Aguilera C; Salvo-Romero E; Alonso C; Rodiño-Janeiro BK; Söderholm JD; Azpiroz F; Santos J
    Gut; 2015 Sep; 64(9):1379-88. PubMed ID: 25209656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.